What?? Mezigdomide, golcadomide, + about 8 more clinical programs? You are confusing (former) Oncogenesis with (former) MoCR. Former has contributed a large fraction of the internally derived pipeline. Latter has delivered nothing. Which of course explains why Onc leader was cut and Gemma retained.
It's not just Lilly, most jobs are like that-these companies are there to make money and hire us to help them be more profitable so their shareholder value gets bigger. I agree that Lilly doesn't care if it's you or the next person doing your job; that's any company though, unless you go work for a small mom-n pop business and make a fraction of what you get here. But we do have pretty nice benefits and a lot of time off, something that many companies don't offer.